Eir Partners takes controlling stake in QuartzBio in growth investment round

QuartzBio, life sciences software company providing portfolio-scale sample and biomarker intelligence for clinical-stage biopharma, secured strategic growth investment from Eir Partners Capital LP, giving investor controlling interest.
Funding targets product development and scaling of vendor-agnostic, AI-enabled platform that consolidates biospecimen tracking, consent status, chain of custody, metadata integrity, and biomarker results to reduce trial delays and data gaps.
QuartzBio cited adoption by multiple top-10 pharmaceutical companies; customers reported monitoring effort reductions of up to 98% and average savings of $250K-$350K per Phase II/III study.
Transaction terms were not disclosed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eir Partners Capital LP published the original content used to generate this news brief on May 13, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.